Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided EPS guidance of $2.80-2.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.78. The company issued revenue guidance of $18.6-19 billion, compared to the consensus revenue estimate of $18.86 billion.Teva Pharmaceutical Industries also updated its FY18 guidance to $2.80-2.95 EPS.
Shares of TEVA opened at $19.98 on Thursday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.03 and a quick ratio of 0.69. The stock has a market capitalization of $20.09 billion, a PE ratio of 5.08, a P/E/G ratio of 1.62 and a beta of 0.71. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The business had revenue of $4.70 billion for the quarter, compared to analyst estimates of $4.75 billion. During the same quarter last year, the company earned $1.02 EPS. The business’s quarterly revenue was down 17.8% on a year-over-year basis. As a group, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.7 EPS for the current year.
In other news, EVP Sven Dethlefs purchased 2,000 shares of the business’s stock in a transaction on Friday, August 3rd. The shares were bought at an average price of $21.92 per share, with a total value of $43,840.00. Following the completion of the transaction, the executive vice president now directly owns 6,445 shares in the company, valued at approximately $141,274.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Richard Daniell sold 2,488 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the transaction, the vice president now directly owns 2,488 shares in the company, valued at approximately $58,940.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,350 shares of company stock worth $239,430. 0.43% of the stock is currently owned by corporate insiders.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: Understanding the different types of bonds
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.